Symbols

ADCT

ADC Therapeutics·NYSE

--(--)

ADCT fundamentals

ADCT Q4 2025 Earnings

ADC Therapeutics (ADCT) released its earnings on Mar 10, 2026: revenue was 23.06M (YoY +36.36%), beat estimates; EPS was -0.04 (YoY +86.21%), beat estimates.

Revenue / YoY

23.06M

+36.36%

EPS / YoY

-0.04

+86.21%

Report date

Mar 10, 2026

ADCT Earnings Call Summary for Q4,2025

Revenue Growth: Q4 2025 net product revenues up 36% YoY to $22.3 million; full-year 2025 revenues stable at $73.6 million.
Pipeline Momentum: LOTIS-5 (ZYNLONTA + rituximab) Phase III trial targeting second-line DLBCL with Q2 2026 readout; LOTIS-7 (ZYNLONTA + glofitamab) shows 90% ORR in Phase Ib.
Financial Strength: $261 million cash runway into 2028; GAAP net loss narrowed 80% YoY to $6.4 million.
Peak Revenue Potential: $600 million to $1 billion in U.S. with new indications, driven by 5-10% second-line DLBCL share ($200-300 million) and bispecific combo expansion.

Earnings

EPS

Revenue

Revenue & Expenses

ADCT has released its 2025 Q4 earnings report, with revenue of 23.06M, reflecting a YoY change of 36.36%, and net profit of -6.41M, showing a YoY change of 79.14%. The Sankey diagram below clearly presents ADCT's revenue sources and cost distribution.

Key Indicators

ADC Therapeutics (ADCT) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

ADC Therapeutics (ADCT)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

ADC Therapeutics (ADCT)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

ADC Therapeutics (ADCT)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown